FDA Inspection
BioMarin Pharmaceutical, Inc.BioMarin Pharmaceutical, Inc. – FDA Inspection, Aug 19, 2024
Record Details
This FDA Inspection record concerns BioMarin Pharmaceutical, Inc., with an inspection on August 19, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · e8b2b049-ebee-414e-99e1-b3ba421792a2
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1251795
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of BioMarin Pharmaceutical, Inc.
11| Date | Classification | Office | Project area |
|---|---|---|---|
| March 26, 2025 | Not classified | San Francisco District Office | |
| November 9, 2018 | Not classified | San Francisco District Office | |
| December 14, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| November 4, 2016 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| April 17, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for BioMarin Pharmaceutical, Inc.
- FDA Inspection 1268309 - 2025-03-26
- FDA Inspection 1076844 - 2018-11-09
- FDA Inspection 1041169 - 2017-12-14
- FDA Inspection 991276 - 2016-11-04
- FDA Inspection 878935 - 2014-04-17
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.